Sustainable Method for Alzheimer's Prediction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-04-11

Study Completion Date

2020-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational study with the aim of validating, in a consistent population sample, with appropriate follow-up, whether EEG connectivity analysis combined with the neuropsychological evaluation and ApoE genotype testing in aMCI could be of help in early identification of converted aMCI as a first-line screening method in order to intercept early those subjects with a high risk for rapid progression to AD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neuroelectrical Biomarkers for Alzheimer's Disease Stages

NCT01880151

Alzheimer Disease

COMPLETED NA

Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease

NCT00955422

Alzheimer's Disease

COMPLETED

Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases

NCT02288000

Alzheimer Disease Battery

UNKNOWN PHASE1

INTERCEPTOR Project: From MCI to Dementia

NCT03834402

Mild Cognitive Impairment Alzheimer Disease

COMPLETED

The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease

NCT00381381

Alzheimer's Disease

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary aim of the present project is to investigate the dynamic connectivity among brain centers by using a mathematical (Small World) approach to the analysis of EEG-related neural networks. The aim is to provide reliable discrimination of amnesic-Mild Cognitive Impairment (a MCI) subjects who, on individual basis, will rapidly convert to Alzheimer Disease (AD) after a relatively brief follow-up. Moreover, keeping in mind that the epsilon-4 allele of the ApoE gene is a genetically determined risk factor for pathogenesis of late-onset AD, a secondary endpoint is introduced to investigate whether the EEG connectivity markers together with a genetically determined risk of dementia as represented by ApoE testing can reach higher sensitivity/specificity for early discrimination of MCI converting to AD

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease Amnestic-Mild Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

aMCI subjects

EEG recording, ApoE testing

EEG

Intervention Type DIAGNOSTIC_TEST

EEG

ApoE

Intervention Type GENETIC

ApoE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EEG

Intervention Type DIAGNOSTIC_TEST

ApoE

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* frontotemporal dementia;
* behavioural variant of frontotemporal dementia;
* vascular dementia;
* extra-pyramidal syndromes;
* reversible dementias (including pseudodementia of depression);
* Lewy body dementia.

* mild AD, as diagnosed by standard protocols including National Institute on Aging-Alzheimer's Association workgroups (McKhann et al. 2011);
* evidence (including magnetic resonance imaging -MRI procedures) of concomitant dementia such as frontotemporal, vascular and reversible dementias (including pseudo-depressive dementia), marked fluctuations in cognitive performance compatible with Lewy body dementia and/or features of mixed dementias;
* evidence of concomitant extrapyramidal symptoms;
* clinical and indirect evidence of depression as revealed by the Geriatric Depression Scale GDS (Yesavage et al. 1982); scores lower than 14 (no depression);
* other psychiatric diseases, epilepsy, drug addiction, alcohol dependence, use of neuro/psychoactive drugs including acetylcholinesterase inhibitors;
* current or previous uncontrolled or complicated systemic diseases (including diabetes mellitus) or traumatic brain injuries.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No